tradingkey.logo

tradingkey.logo
怜玢


Alkermes Plc

ALKS
りォッチリストに远加
48.990USD
-1.040-2.08%
終倀 07-31 16:00ET15分遅れの株䟡
8.22B時䟡総額
52.69盎近12ヶ月PER

詳现情報 Alkermes Plc 䌁業名

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plcの䌁業情報


䌁業コヌドALKS
䌚瀟名Alkermes Plc
䞊堎日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)
埓業員数1800
蚌刞皮類Ordinary Share
決算期末Jul 16
本瀟所圚地Connaught House
郜垂DUBLIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Ireland
郵䟿番号D04 C5Y6
電話番号35317728000
りェブサむトhttps://www.alkermes.com/
䌁業コヌドALKS
䞊堎日Jul 16, 1991
最高経営責任者「CEO」Pops (Richard F)

Alkermes Plcの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
227.49K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
73.39K
-5.45%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
25.68K
-7.79%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
18.22K
+25.61%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
227.49K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
73.39K
-5.45%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%

よくある質問

Alkermes Plcの䞊䜍5名の株䞻は誰ですか


Alkermes Plcの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Richard F. Pops

Alkermes PlcALKSの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Alkermes Plcの株匏を保有しおいる機関は783瀟あり、保有株匏の総垂堎䟡倀は玄182.39Mで、党䜓の109.43%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-11997400.00増加しおいたす。

Alkermes Plcの最倧の収益源は䜕ですか


2026Q1においお、VIVITROL郚門がAlkermes Plcにずっお最倧の収益を生み出しおおり、その金額は467.91Mで、党収益の31.70%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。